American Academy of Dermatology

In the future, atopic dermatitis (AD) may need to be targeted with different drugs and tailored for different AD populations, particularly if initial treatment targeting all phenotypes fails, says Emma Guttman-Yassky, M.D., Ph.D.

Staphylococcus aureus infections are becoming more challenging to treat due to methicillin-resistant Staphylococcus aureus (MRSA). A better understanding of cutaneous immune mechanisms will identify specific immune mechanisms to target for future vaccines and immunotherapies to ultimately address this serious public health threat.

The cutaneous side effects of targeted therapies and immunotherapy for melanoma can complicate treatment and become a burden to patients. Dermatologists must aggressively address these side effects for a more ideal management and better quality of life for their melanoma patients.

New atopic dermatitis treatment developments earn “hot topic” status at AAD.

Skin concerns and treatment approaches differ for and among patients with skin of color.

If you want to get paid promptly in 2019, don't get too comfortable with biopsy codes you've been using for years, says Alexander Miller, M.D., F.A.A.D. Read more from his presentation on coding and office management from the American Academy of Dermatology Annual Meeting in Washington, D.C.

As an expert on coding and office management, Mark D. Kaufmann, M.D., explained important role the AMA's Specialty Society Relative Value Update Committee (RUC) plays in code valuation during his presentation at the American Academy of Dermatology Annual Meeting in Washington, D.C.

With a crowded indication that includes 14 systemic agents, is there really room for tyrosine kinase 2 (Tyk2) inhibitors to treat psoriasis? This physician thinks so.

Drug-device combination, VP-102, met all primary and secondary endpoints in the parallel Cantharidin Application in Molluscum Patients (CAMP)-1 and CAMP-2 trials.

The development of new biologics targeting a variety of dermatoses is on the upswing with some treatments coming to the clinic as early as this year, according to April Armstrong, M.D. who discussed the topic at the American Academy of Dermatology Spring Meeting in Washington, D.C.

As demand for quick fixes soars, so do complications. Dr. Jennifer Chwalek advises on how to identify, fix and avoid them.

Dr. Lawrence Eichenfield discusses a better understanding of disease pathogenesis, available therapies and proactive treatment approach improves the outlook for managing atopic dermatitis.

From fat reduction to skin tightening and tone, Dr. Neil Sadick offers keys for best outcomes when combining energy-based devices.

Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping. Andrew Blauvelt, M.D. discussed new drugs in the pipeline during American Academy of Dermatology Annual Meeting in Washington, D.C.

To help providers have a greater understanding of the efforts of the FDA to ensure all drugs are of pharmaceutical quality, Michael Kopcha, Ph.D., RPh, director of the FDA’s Office of Pharmaceutical Quality presented on the topic during the American Academy of Dermatology’s Annual Meeting in Washington, D.C.

Laura Marquart, M.D., FAAD, medical officer with the FDA’s Center for Devices and Radiological Health (CDRH), reviewed how the FDA approaches, reviews, and approves medical devices integral to dermatologic care at the American Academy of Dermatology’s annual meeting in Washington, D.C. Learn how this process can affect patient care in this article.

While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.

Longer-lasting treatment for vitiligo could be available within the next few years, according to research presented at the American Academy of Dermatology Annual Meeting in Washington, D.C.

Treating chronic inflammatory skin conditions during pregnancy can be difficult because the therapies dermatologists prescribe can affect the unborn infant. See what insights this physician offers on managing chronic inflammatory skin conditions in pregnant patients.

Dr. Jacob Mashiah offers tips for optimally treating patients with sweating disease.

Dr. Jonathan Silverberg offers tips at AAD 2019 for diagnosing and managing atopic dermatitis in adults.

When it comes to addressing skincare concerns, some combination therapies work better than others.

Knowledge of epidermal structure and function can improve understanding of disease pathogenesis and ultimately help dermatology providers evaluate and diagnose patients.

Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.

The American Academy of Dermatology annual meeting will be held from March 1-5 in Washington, D.C.

Monitoring changes in patients with melanoma can be tricky. Some changes present slowly and in tiny ways. Using imaging technologies to track these changes can help achieve an accurate diagnosis.

Frontal fibrosing alopecia is a condition that is increasing in epidemic proportions, says Jerry Shapiro, M.D., in a presentation given at the 2018 AAD Summer Meeting.

When conducting skin treatments, addressing pain ― whether minor or more serious ― may make an uncomfortable procedure more tolerable for patients. Dr. Peter Lio outlines some steps physicians can follow to make patients more comfortable.

There are many reasons why patients resist following instructions, but a comprehensive approach can help doctors change behavior.